Open company graph database — free web & API
Login

Kubota Pharmaceutical Holdings Co., Ltd.

窪田製薬ホールディングス株式会社
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
8
Related companies
4
§01

Basic information

BASIC
Head office
15-37, 1-chome Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan
Chief executive
Dr. Ryo Kubota, MD, PhD
Capital
33,000,000 JPY
Employees (non-consolidated)
8 people
Employees (consolidated)
Start date
2015-12-01
End date
§02

Websites

1 DOMAINS
§03

Business

2
Research and DevelopmentPharmaceuticals
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kubota Vision Inc.
Group Subsidiary
Nerima Keniku Association Hospital, Medical Corporation Keniku Association
Customer
Yukafu Taiyo Co., Ltd.
Customer
Laboratoires KÔL
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

44 EVENTS

Established Acugen Neuropeutics Inc. in Seattle, Washington, USA, to develop treatments for degenerative eye diseases and screening systems for pharmaceuticals.Sources

Changed company name to Acucela Inc.Sources

Initiated search for visual cycle modulators.Sources

Relocated all departments, including headquarters and research facilities, to Bellingham, Washington, USA.Sources

Commenced development of the visual cycle modulator 'Emixstat Sodium Salt' for retinal disease treatment.Sources

Opened Acucela Inc. Japan office in Shinagawa-ku, Tokyo.Sources

Submitted IND for 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration to the FDA.Sources

Initiated Phase 1 clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.Sources

Entered joint development and joint sales agreement with Otsuka Pharmaceutical Co., Ltd. for our key compound 'Emixstat Sodium Salt'.Sources

FDA designated 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration as Fast Track.Sources

Relocated headquarters, including administration and clinical development divisions, to Seattle, Washington.Sources

Initiated Phase 2b/3 clinical trials of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.Sources

Moved Acucela Inc. Japan office to Shibuya-ku, Tokyo.Sources

Listed on the Tokyo Stock Exchange Mothers market.Sources

Announced results of Phase 2a clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.Sources

Established subsidiary Acucela Japan Co., Ltd. (now Kubota Pharmaceutical Holdings Co., Ltd.) in Shibuya-ku, Tokyo.Sources

Established: December 2015Sources

EstablishedSources

Acquired exclusive rights to develop cataract drug candidates from YouHealth.Sources

Signed exclusive agreement with the University of Manchester for development and commercialization of gene therapy technology for retinal degenerative diseases.Sources

Initiated Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy.Sources

Announced results of Phase 2b/3 clinical trial of 'Emixstat Hydrochloride' for dry age-related macular degeneration with geographic atrophy.Sources

Ended joint development and joint sales agreement for 'Emixstat Hydrochloride' with Otsuka Pharmaceutical Co., Ltd.Sources

Implemented headquarter relocation to Japan via triangular merger, and Kubota Pharmaceutical Holdings Inc. made AcuSera Inc. a wholly-owned subsidiary.Sources

Kubota Pharmaceutical Holdings Inc. listed on the Tokyo Stock Exchange Mothers market.Sources

Entered into an option agreement with EyeMedics Inc. for exclusive rights to worldwide manufacturing, development, and sales of a new biomimetic technology.Sources

FDA designated 'Emixstat Hydrochloride' for Stargardt disease as an orphan drug.Sources

Initiated Phase 2a clinical trial of 'Emixstat Hydrochloride' for Stargardt disease.Sources

Commenced in-house development of ophthalmic medical device solutions for home and remote care.Sources

Relocated headquarters to Chiyoda-ku, Tokyo.Sources

Signed joint development agreement with SIRION Biotech GmbH for gene delivery technology aimed at ophthalmic gene therapy research.Sources

Announced results of Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy.Sources

Announced results of Phase 2a clinical trial of 'Emixstat Hydrochloride' for Stargardt disease.Sources

Initiated clinical trial of ophthalmic home and remote monitoring device 'PBOS'.Sources

Announced results of clinical trial of ophthalmic home and remote monitoring device 'PBOS'.Sources

Initiated Phase III clinical trial of 'Emixstat Hydrochloride' for Stargardt disease.Sources

Signed contract to develop a small OCT (optical coherence tomography) device for NASA's deep space missions.Sources

EMA designated 'Emixstat Hydrochloride' for Stargardt disease as an orphan drug.Sources

Changed the trade name of wholly-owned subsidiary AcuSera Inc. to Kubota Vision Inc.Sources

FDA selected Phase III clinical trial of 'Emixstat Hydrochloride' for Stargardt disease for the Orphan Products Clinical Trials Grants Program.Sources

The wearable myopia device 'Kubota Glasses', aimed at suppressing and treating myopia progression, successfully completed a proof-of-concept (POC) test using wearable devices.Sources

The wearable myopia device 'Kubota Glasses', aimed at suppressing and treating myopia progression, obtained a medical device manufacturing license in Taiwan.Sources

Obtained ISO 13485:2016 international standard certification.Sources

Kubota Pharmaceutical Holdings Co., Ltd. transitioned to the Growth Market segment of the Tokyo Stock Exchange.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information3011001108646
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
窪田製薬ホールディングス株式会社
Trade name (kana)
クボタセイヤクホールディングス
Name in English
Corporation type
301
Address
〒107-0062 東京都港区南青山1丁目15番37号
Postal code
1070062
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-12-17
Update date
2023-06-21
Change date
2023-06-16
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1642593
METI gBizINFO3011001108646
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
3011001108646
Trade name
窪田製薬ホールディングス株式会社
Trade name (kana)
クボタセイヤクホールディングス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区南青山1丁目15番37号
Postal code
1070062
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
南青山1丁目15番37号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役会長、社長兼最高経営責任者  窪田 良
Capital
577576000
Employees
7
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-06-21
Key information
3011001108646
§09

Sources & updates

SOURCES
↑